Early suppressive effects of chemotherapy on recovery of bone marrow megakaryocyte precursors: Possible relationship to platelet recovery

Stem Cells

Volumn 14, Issue SUPPL. 1, 1996, Pages 31-37

  Warren, M Kim ^a   Zujewski, Joanne ^b   Rose, Wendy L ^a   Szabo, Janet M ^b   O'Shaughnessy, Joyce A ^b   Halverson, David C ^b   Cowan, Kenneth H ^b   Gress, Ronald E ^b   Schwartz, Gretchen N ^b  

^a Poietic Technologies   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

CD34+ cells; Chemotherapy; ELISA; Glycoprotein GPIIb IIIa; Megakaryocytes

Indexed keywords

ANTINEOPLASTIC AGENT; CALF PROTOCOL; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FIBRINOGEN RECEPTOR; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; INTERLEUKIN 3; PIXY321 FUSION PROTEIN, RECOMBINANT; STEM CELL FACTOR;

ARTICLE; BIOSYNTHESIS; BLOOD CELL COUNT; BONE MARROW CELL; BREAST TUMOR; CASE CONTROL STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MEGAKARYOCYTE; METABOLISM; PHYSIOLOGY; THROMBOCYTE; THROMBOCYTOPENIA; TIME;

ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD CELL COUNT; BLOOD PLATELETS; BONE MARROW CELLS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUOROURACIL; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-3; LEUCOVORIN; MEGAKARYOCYTES; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECOMBINANT FUSION PROTEINS; STEM CELL FACTOR; THROMBOCYTOPENIA; TIME FACTORS;

EID: 0030307555     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.5530140704     Document Type: Article

References (20)

1. Fisher DC, Peters WP. Advances in the clinical use of granulocyte colony-stimulating factor and granulocyte-macrophage stimulating factor to intensify cancer chemotherapy. Curr Opin Hematol 1994;1:221-227.
2. Bishop JF. Platelet support and the use of cytokines. STEM CELLS 1994;12:370-377.
3. Morstyn G, Campbell L, Liescheke G et al. Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration therapy. J Clin Oncol 1989;7:1554-1562.
4. Vadhan-Raj S, Broxmeyer HE, Hittelman WN et al. Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level. J Clin Oncol 1992;10:1266-1277.
5. O'Shaughnessy JA, Denicoff AM, Venson DJ et al. A dose intensity study of FLAG (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer. Ann Oncol 1994;5:709-716.
6. O'Shaughnessy JA, Venzon DJ, Gossard M et al. A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony stimulating factor in advanced breast cancer patients treated with FLAG (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy. Blood 1995;86:2913-2921.
7. O'Shaughnessy JA, Tolcher A, Riseberg D et al. Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclosphosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in patients with advanced breast cancer. Blood 1996;87:2205-2211.
8. Karpatkin S. Autoimmune thrombocytopenic purpura. Blood 1980;56:329-343.
9. Nash RA, Burstein SA, Storb R et al. Thrombocytopenia in dogs induced by granulocyte-macrophage colony-stimulating factor: increased destruction of circulating platelets. Blood 1995;86:1765-1775.
10. Yeager AM, Levin FC, Levin J. Effects of cyclophosphamide on murine bone marrow and splenic megakaryocyte-CFC, granulocyte-macrophage-CFC, and peripheral blood cell levels. J Cell Physiol 1982;112:222-228.
11. Petursson SR, Chervenick PA. Megakaryocytopoiesis and granulopoiesis following cyclophosphamide. J Lab Clin Med 1982;100:682-694.
12. v mice treated with 5-fluorouracil. Exp Hematol 1993;21:414-419.
13. Ebbe S, Yee T, Phalen E. 5-Fluorouracil-induced thrombocytosis in mice is independent of the spleen and can be partially reproduced by repeated doses of cytosine arabinoside. Exp Hematol 1989;17:822-826.
14. + cells and the GPIIb/IIIa marker. Exp Hematol 1993;21:1473-1479.
15. + cell expansion and expression of lineage markers during liquid culture of human progenitor cells. STEM CELLS 1995;13:167-174.
16. Schwartz GN, Warren MK, Sakano K et al. Comparative effects of insulin-like growth factor II (IGF-II) and IGF-II mutants specific for IGF-II/CIM6-P or IGF-I receptors on in vitro hematopoiesis. STEM CELLS 1996;14:337-350.
17. Schwartz GN, Hudgins WR, Perdue JF. Glycosylated insulin-like growth factor II promoted expansion of granulocyte-macrophage colony-forming cells in serum-deprived liquid cultures of human peripheral blood cells. Exp Hematol 1993;21:1447-1454.
18. Coller BS, Peerschke EI, Scudder LE et al. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983;72:325-338.
19. Schwartz GN, Hakim F, Zujewski J et al. Early suppressive effect of chemotherapy and cytokine treatment on committed versus primitive haemopoietic progenitors in patient bone marrow. Br J Haematol 1996;92:537-547.
20. Siena S, Bregni M, Bonsi L et al. Increase in peripheral blood megakaryocyte progenitors following cancer therapy with high dose cyclophosphamide and hematopoietic growth factors. Exp Hematol 1993;21:1583-1590.